Aspira (AWHL) director increases stake with stock and warrants on 09/17/2025

Rhea-AI Filing Summary

John D. Fraser, a director of Aspira Women's Health Inc. (AWHL), reported purchases on 09/17/2025. He acquired 16,389 shares of common stock at $0.45 per share and purchased 12,292 warrants (exercise price $0.75, exercisable 09/17/2025, expiring 09/17/2030) covering 12,292 shares. After these transactions he reports beneficial ownership of 566,393 shares directly and 291,554 indirectly through Seamark Capital; 981,549 derivative securities are shown as owned.

Positive

• Director purchase disclosed: John D. Fraser acquired 16,389 shares at $0.45, signaling insider buying.
• Warrants added: Purchase of 12,292 warrants with clear exercise ($0.75) and expiration (09/17/2030) terms.
• Covers direct and indirect ownership: Filing shows 566,393 shares direct and 291,554 indirect via Seamark Capital, improving transparency.

Negative

• None.

Insights

Securities Analyst

TL;DR: Director purchased shares and warrants at modest prices, increasing both direct and derivative holdings.

The Form 4 shows a single reporting person, John D. Fraser, executing purchases on 09/17/2025: 16,389 common shares at $0.45 each and 12,292 warrants with a $0.75 exercise price. Post-transaction holdings include direct and indirect positions, including a large reported count of derivative securities (981,549). These entries are routine insider purchase disclosures and provide transparency on Fraser's ownership stake and potential upside if warrants are exercised.

Corporate Governance Expert

TL;DR: Insider buying is disclosure-compliant and indicates increased insider alignment with shareholders.

The filing is properly executed by a director and signed on 09/18/2025. It identifies both direct ownership and indirect ownership via Seamark Capital, and it discloses exercise terms and expiration for the warrants. The disclosure appears complete for the transactions listed; no amendments or inconsistencies are evident within the provided content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Fraser John D

(Last) (First) (Middle)

C/O ASPIRA WOMEN'S HEALTH INC

12117 BEE CAVES RD, BLDG 3-100

(Street)

AUSTIN, PA 78738

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aspira Women's Health Inc. [ AWHL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		P		16,389	A	$0.45	566,393	D
Common Stock								291,554	I	By Seamark Capital

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrant (Right to Buy)	$0.75	09/17/2025		P		12,292		09/17/2025	09/17/2030	Common Stock, par value $0.001	12,292	$0	981,549	D

Explanation of Responses:

	/s/ John D. Fraser	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AWHL director John D. Fraser purchase on 09/17/2025?

He purchased 16,389 common shares at $0.45 per share and 12,292 warrants (exercise price $0.75, exercisable 09/17/2025, expiring 09/17/2030).

How many AWHL shares does John D. Fraser beneficially own after the reported transactions?

The filing reports 566,393 shares owned directly and 291,554 shares owned indirectly through Seamark Capital.

What is the exercise price and expiration date of the warrants reported by John D. Fraser?

The warrants have an exercise price of $0.75, are exercisable on 09/17/2025 and expire on 09/17/2030.

Was the Form 4 filed jointly or by one reporting person for AWHL?

The Form indicates it was filed by one reporting person (John D. Fraser).

Who signed the Form 4 for Aspira Women's Health (AWHL)?

The filing is signed /s/ John D. Fraser with the signature date 09/18/2025.